In a renal transplant patient, antidepressant treatment with a selective serotonin reuptake inhibitor may interact adversely with the immunosuppressant ciclosporin.
CASE HISTORY
A man aged 53 was admitted with dizziness, slurred speech and right-sided weakness. He had a history of vertebrobasilar insuf®ciency and eighteen months earlier he had undergone renal transplantation for end-stage renal failure of unknown aetiology. Blood pressure was 150/80 mmHg, pulse rate was 80 per minute and he was afebrile. He had a right intranuclear ophthalmoplegia, a right facial nerve upper motor neuron type palsy and grade 4/5 weakness on the right side. Computed tomography of the brain showed a left pontine infarct and an old infarct in the right external capsule and head of caudate. He deteriorated over the next few days and became tetraplegic and aphasic. Medication included azathioprine 125 mg daily, ciclosporin 100 mg twice daily, prednisolone 5 mg daily, atorvastatin 5 mg daily and aspirin 160 mg daily. When he became depressed and tearful, sertraline 50 mg daily was prescribed. Five days after starting sertraline, he developed generalized tremor, profuse sweating, tachycardia and a fever of 428C.
Respiratory rate was 40 per minute, heart rate was 180 per minute and his blood pressure¯uctuated between 180/ 100 and 210/120 mmHg. Capillary blood glucose was 6 mmol/L and pulse oximetry showed oxygenation of 98% on room air. Neurological examination revealed ankle clonus and generalized hyperre¯exia. There was no sign of meningism and papilloedema was absent.
Blood tests taken at the time were as follows: haemoglobin 14.2 g/dL, platelets 338610 9 /L, white cells 12.6610 9 /L, sodium 141 mmol/L, potassium 5.2 mmol/L, urea 9.7 mmol/L and creatinine 148 mmol/L. Creatine phosphokinase was slightly raised at 365 iu/L (reference range 42±218). Liver and thyroid function tests were normal. He was not metabolically acidotic (pH 7.38). Urine myoglobin was not detected and 24-hour urine noradrenaline and adrenaline levels were normal. His creatinine clearance was 49 mL/min. Ciclosporin trough level was 103 (therapeutic range 100±150). Blood and urine cultures were negative.
Sertraline was discontinued. He was treated with intravenous labetalol infusion at 1 mg/min, promethazine 25 mg twice daily, paracetamol via nasogastric tube, and cooling care (tepid sponging and ice pack). Pulse rate, blood pressure and temperature returned to normal within 12 hours. Labetalol, promethazine and paracetamol were discontinued 2 days later and he remained stable.
COMMENT
Serotonin syndrome is caused by central serotoninergic 5HT 1A and 5HT 2 receptor hyperstimulation and is characterized by changes in mental state (agitation, excitement, hypomania), motor system abnormalities (myoclonus, hyperre¯exia, hemiballismus, ataxia) and autonomic manifestations (tremor, diarrhoea, fever) 1 . Selective serotonin reuptake inhibitors (SSRI), selective noradrenaline reuptake inhibitors, serotonin precursors (e.g. tryptophan, L-dopa), amphetamine derivatives, tricyclic antidepressants, opioids and opioid-like agents in either therapeutic doses and overdoses have been implicated in the development of this syndrome. The combination of monoamine oxidase inhibitors (MAOIs) with SSRIs is the most common cause of the syndrome 2 . MAOIs and SSRIs increase serotonin concentration in the central nervous system by inhibiting degradation and reuptake of serotonin respectively. They act synergistically, leading to high levels of serotonin in blood 3 . To our knowledge this is the ®rst report of serotonin syndrome in a patient taking a SSRI together with ciclosporin. We propose two possible mechanisms to account for this adverse effect. First, both drugs are extensively protein-bound and the competition for protein-binding may lead to an increased level of free circulating sertraline. Secondly, in mice ciclosporin enhances brain serotoninergic neural activity with increased serotonin turnover in the brain resulting in increased irritability 4 . The additional sertraline may aggravate this central nervous effect. It is unlikely that our patient's mild renal impairment contributed to the serotonin syndrome since according to the manufacturer (P®zer) sertraline is metabolized mainly by the liver.
Our patient had been stable for eighteen months on immunosuppressive therapy consisting of ciclosporin, azathioprine and prednisolone. The development of serotonin syndrome ®ve days after the introduction of sertraline strongly suggests a direct causal role. In view of the serotoninergic enhancement effect of ciclosporin in the central nervous system we think it likely that ciclosporin acted synergistically with sertraline to produce serotonin syndrome. The differential diagnosis included neuroleptic malignant syndrome, which is precipitated by the dopamine-antagonizing effect of neuroleptic drugs such as haloperidol and clozapine. However, the patient had not received any neuroleptic drugs. We present a case of renal and systemic vasculitis that was temporally associated with the clinical presentation of renal cell carcinoma. Although such associations are rare, vasculitis affecting the kidney does appear to confer an increased risk of renal cancer, particularly in the presence of Wegener's granulomatosis.
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CASE HISTORY
A man of 53 was admitted with a four-week history of rash, arthralgia and malaise. He had also noticed peri-oral numbness and intermittent numbness affecting his right thigh. There was no history of oral ulceration. He had previously been well apart from a history of hypertension, controlled by nifedipine. He was a non-smoker.
On examination he was overweight (115 kg). He had numerous splinter haemorrhages, mild episcleritis and vasculitic skin lesions over the feet. There was diminished pin-prick sensation in the peri-oral region and over the toes on the right. Red cells and granular casts were seen on urine microscopy. Haemoglobin was 13.1 g/dL, white cell count 15.3610 9 /L with pronounced eosinophilia (neutrophils 8.2, lymphocytes 1.1, eosinophils 5.6), and platelets 370610 9 /L. Erythrocyte sedimentation rate was 76 mm/h, C-reactive protein 86 mg/L. Liver function tests were normal. Serum creatinine was 85 mmol/L, creatinine clearance 134 mL/min, and 24-hour urinary protein excretion 1.23 g. Antinuclear antibody, ANCA, rheumatoid factor, and tests for cryoglobulins and glomerular basement membrane antibodies were negative. Complement levels were normal. Blood cultures were sterile and an echocardiogram was normal. A chest X-ray was dif®cult to interpret because of the patient's size, and a CT of the chest was arranged. Renal ultrasound was reported as demonstrating two normal-sized kidneys with increased parenchymal echogenicity, consistent with intrinsic renal disease.
Systemic vasculitis was suspected and the patient was started on oral prednisolone 60 mg daily. Diagnostic renal biopsy was performed four days later. The specimen contained 35 glomeruli, 5 of which showed segmental areas of ®brinoid necrosis with in¯ammatory exudates and a crescentic epithelial reaction. One other glomerulus showed an old segmental lesion with chronic scarring. Immuno¯uorescence staining was negative for all conjugates. There was mild tubular and interstitial atrophy but minimal lymphocytic in®ltration and no evidence of tubulitis.
Oral cyclophosphamide was started, with improvement of symptoms and rapid resolution of the eosinophilia. A CT of the chest four weeks after the biopsy showed normal lung ®elds but a lesion arising from the left kidney (Figure 1) . Repeat scanning after six weeks showed a similar appearance. At exploratory laparotomy a tumour was found arising from the left kidney with no evidence of intra-abdominal spread. Nephrectomy was performed, and histological examination of the specimen showed a
